Backgroung: Brugada Syndrome (BrS) is an arrhythmogenic disease associated with sudden
Introduction
The Brugada Syndrome (BrS) is an arrhythmogenic disease 1 , with a heterogeneous genetic background [2] [3] [4] [5] , usually diagnosed during adulthood. Spontaneous type 1 ECG pattern and symptoms are predictive risk factors for life-threatening arrhythmias (LTA) in adults 2 but, given the rarity of BrS in the pediatric population, risk stratification in the young is difficult.
In a Japanese study 6 screening elementary school children, only 0.02% of 22,000 displayed a Brugada type related ECG with only one case of spontaneous type 1 ECG pattern.
The largest pediatric BrS population studied so far included 30 European children and suggested that fever, symptoms and spontaneous type 1 ECG pattern were associated with LTA 7 . Drug-induced BrS in children has been reported 8 .
In the largest series of BrS in adulthood 2 , very few patients were below age 20.
Our aim was to describe the clinical presentation of BrS below age 19, to identify prognostic factors useful to improve risk stratification, and to propose a data-based approach to management of this specific population.
Methods

Clinical Data
Data on 106 patients below age 19 were collected from 16 European tertiary centers;
29 of them had been described originally in 2007 7 . Inclusion required a type 1 Brugada ECG pattern either spontaneously or after challenge with a sodium channel blocker (ajmaline or flecainide). Patients displaying only fever-induced Brugada type 1 ECG pattern were included in the spontaneous group. The type 1 ECG pattern was defined according to consensus guidelines as coved ST-elevation ≥ 0.2mV at its peak in at least one right precordial leads (V1 to V3 in the 2 nd , 3 rd or 4 th intercostal spaces) 9, 10 .
Recorded data included: family history; past medical history; follow-up data from hospitalization reports, specialist and general cardiology clinical letters; and direct follow-up contact with patients. Syncope was considered of arrhythmic origin when a sudden loss of consciousness occurs without any other explanation.
Twelve-lead ECGs at baseline and, if needed, during drug-challenge, were performed according to the guidelines 10 . The 12-lead ECGs were first analyzed by an expert cardiologist in the referring hospital. ECG parameters were then collected at baseline and during drug challenge. Either intravenous ajmaline (1mg/kg body weight) or flecainide (2mg/kg body weight) were used depending on drug availability at the participating centers.
A baseline electrophysiological study (EPS) was performed in 22 patients at the clinical judgment of the expert cardiologist. A maximum of three ventricular extrastimuli with a minimum coupling interval of 200ms were delivered from at least one right ventricular site unless VF and/or sustained VT were induced at an earlier stage.
At diagnosis, patients were considered symptomatic if they had experienced aborted SCD (aSCD), ventricular arrhythmias [non-sustained VT (NSVT), VT or VF] or syncope.
During follow-up, patients were considered to have a LTA event if sudden death, documented VT or VF occurred or if an appropriate ICD shock was documented.
Genetic Analysis
Genetic testing was conducted according to guidelines and was approved by local ethics committees for research or regular clinical purposes. Informed written consent was obtained either from the parents or the patient (if above age 18). Genomic DNA was extracted from peripheral blood leukocytes using standard protocols. All exons of SCN5A
were amplified by PCR. PCR products were screened for an SCN5A mutation using denaturing high-performance liquid chromatography and/or direct DNA sequencing. In probands, all exons of SCN5A were screened whereas only the specific exon was sequenced if a rare variant had been identified previously in the family.
Statistical Analysis
Data were analyzed with SAS packages (SAS Institute Inc., Cary, NC The authors had full access to and take full responsibility for the integrity of the data.
All authors have read and agree to the manuscript as written. with supra-ventricular tachycardia (SVT) and 3 who experienced subjective symptoms (presyncope or palpitations) were considered asymptomatic at diagnosis for the purposes of our survival analyses. Table 3 ): Thirty-six (34%) patients presented with a spontaneous type 1 ECG pattern, of whom 14 (39%) were symptomatic at diagnosis. Among these 36 patients, 7 displayed the type 1 ECG pattern only during a fever episode ( Figure 1 ). The 70 (66%) remaining patients presented with a type 1 pattern after provocation testing, of whom only 7 (10%) were symptomatic at diagnosis. Males were more common in the spontaneous group (sex ratio= 2.6) whereas females were more common in the drug-induced group (sex ratio=0.84 [p=0.013]). A spontaneous type 1 ECG pattern was significantly associated with male gender (p=0.013) and symptoms at diagnosis (p=0.0007).
Results
Population
ECG findings at diagnosis (supplemental material;
Genetics (Table 1) : Seventy-five patients, belonging to 62 families, underwent SCN5A
analysis. Thirty-two (43%) were pediatric probands in whom all exons were tested: fifteen (47%) tested positive. In 43 patients, direct sequencing was performed to detect the SCN5A mutation identified in the family. Overall 58/75 (77%) were genotype positive (Supplemental material Table 1 ).
Drug Challenge/EPS
Drug challenges were performed in 70 (66%) patients with ajmaline (n= 42) or flecainide (n=27; unknown=1). Median ages at challenges were 14.3±3.7 years for ajmaline and 13.4±4.5 years for flecainide (p=0.38). Two patients (15.6 and 16.7 years of age both SCN5A positive) developed NSVT for which no specific therapy was needed. No other adverse events were observed. ECG parameters at baseline, before and during drug challenge are summarized in Supplemental material; Table 4 . EPS were performed in 22 (21%) patients, nine of whom were symptomatic at diagnosis, and were reported as "positive" or VF inducible in 9 (41%).
Treatment
An ICD was implanted in 22 (21%) patients, of whom 18 received an endocardial ICD and 3 a system with an epicardial ventricular lead and a subcutaneous or intercostal coil.
Eighteen ICDs were implanted as primary prevention whilst four patients were implanted after an aSCD or VT. Four pacemakers were implanted in SCN5A positive patients with symptomatic sinus node dysfunction.
Hydroquinidine was started in 11 (10%) patients: 9 (8%) with a spontaneous type 1 ECG pattern; and 8 following arrhythmic events. Blood concentrations of quinidine were only available in 3 patients, and in the therapeutic range as defined by the local laboratory.
No side effects were reported for hydroquinidine.
Follow-up
During a median follow-up of 54 [15- Table 2) . Two had a drug-induced type 1 ECG pattern at diagnosis.
Seven (70%) were symptomatic at diagnosis [aSCD (n=3), syncope (n=3) and VT (n=1)].
Nine (90%) carried a SCN5A mutation.
A LTA during follow-up was experienced by 2 out of 9 (22%) patients with a positive EPS, and by 1 of 13(8%) patients who had a negative EPS (p=0.85). Two (11%) from the 18 primary prevention ICD patients had appropriate ICD shocks. Eight (73%) of the 11 patients receiving hydroquinidine remained free from LTA after initiation of therapy.
Another 6 (6%) were syncopal without documented arrhythmia. Four (4%) had SVT:
two atrial flutter treated by catheter ablation and two atrial tachycardia. A flow-chart of clinical presentation and follow-up is presented in Figure 2 and a clinical description of LTA events during follow-up can be found in supplementary data.
ICD complications
Serious ICD-related complications occurred in 9 (41%) of the 22 patients including lead failures (n=4), inappropriate shocks (n=4), endocarditis with re-implantation (n=2) and hemothorax (n=1). Two patients had both lead failure and inappropriate shocks or endocarditis. All complications were related to endocardial devices except the hemothorax, which appeared in the early post-operative period after epicardial ventricular lead implantation.
Predictive factors for LTA
Nine of the 10 patients who experienced LTA were SCN5A carriers ( The Figure 3 shows the time to first LTA event in the following groups: symptomatic at diagnosis (S+); asymptomatic at diagnosis (S-); spontaneous type 1 ECG pattern (ECG+) and drug induced type 1 ECG pattern (ECG-) (global p-value=0.006).
Following univariate analysis, we divided patients in different groups ( Table 3) :
group S+/ECG+ (n=14); group S+/ECG-(n=7); group S-/ECG+ (n=22) and group S-/ECG-(n=63). These four groups showed differences in time to first LTA event (global pvalue=0.006; Figure 4 
Discussion
Three of the 8 patients reported in the first description of BrS 1 were under 8 years of age. However, few data are available on the natural history in children 7, 8, 11 and the management of this special population has been inconsistent 12 . This study represents the largest series of pediatric BrS patients described as yet. As in the adult population, we show that a spontaneous type 1 ECG pattern and symptoms at diagnosis are predictive of a shorter time to first LTA event.
Brugada syndrome in children
Our cohort showed no significant gender difference in BrS carriers up to age 15. A trend in male predominance then develops after this age and presumably continues into adulthood. This reflects the likely role of androgens in BrS, which may involve circadian rhythm of testosterone release 13, 14 .
More than half of our population was diagnosed during family screening using sodium channel blocker challenge. , which is 20 times more common in febrile patients 18 . In this study, fever triggered up to a quarter of all arrhythmic events. Dumaine et al 19 have demonstrated a diminished inward current through mutant cardiac sodium channels due to changes in biophysical properties at higher temperatures. Despite this evidence the mechanism of fever-induced BrS remains incompletely understood. Early childhood might be a period of high risk because of the frequent occurrence of fever. Even if the rate of arrhythmic events during fever is unpredictable we still advise aggressive treatment with antipyretics. We also advise the recording of a standard ECG when BrS children are admitted to hospital with a fever. If the ECG is abnormal, they should be monitored until their ECG returns to its usual baseline.
We chose to include in the same group patients who displayed a type 1 ECG pattern spontaneously or only with fever due to a lack of power resulting from low numbers. These 2 subgroups may not, however, have the same arrhythmic risk and need to be evaluated separately in a larger cohort.
SCN5A mutation status and its implications
SCN5A mutations were found in a higher proportion of patients than expected. In particular we found a 47% prevalence of SCN5A mutations in index patients, more than double that seen in adults with BrS
20
. Given the important role of conduction defects and increasing age in the pathophysiology of the disease 21, 22 , one can speculate that the impairment of conduction associated with SCN5A mutations facilitates the development of BrS in the pediatric population.
All 9 genotyped patients who experienced LTA had a SCN5A mutation, but 7 also displayed a spontaneous type 1 ECG pattern. By contrast, none of the 17 genotype-negative patients, suffered a LTA event. Thus, in our cohort the presence of a SCN5A mutation may be necessary, but is insufficient on its own for the development of LTA 23, 24 . These results should, however, be treated cautiously due to the low number of patients and the high prevalence of SCN5A mutations. Further studies are needed to assess if the presence or absence of a SCN5A mutation may be useful for risk assessment in the young.
Therapy in the young
An ICD was implanted in 22 patients with a high subsequent complication rate (41%).
This high risk for adverse events is probably compounded in this young population by rapid physical growth and a high level of physical activity. The incidence may be decreased by using the subcutaneous ICD or subcutaneous coil 25 . In a small and selected group of paediatric patients, Pettit et al. 26 suggests a lower incidence of inappropriate shocks or reoperations with a subcutaneous ICD compared to a transvenous ICD.
Hydroquinidine may be an attractive alternative, and most of our patients treated with hydroquinidine remained asymptomatic. In the adult population hydroquinidine tends to be a safe alternative 28, 29 but given the small number of patients and the relatively short follow-up in this cohort, larger-scale studies are needed.
Nonetheless we advise consideration of ICD implantation or quinidine therapy in patients with a spontaneous type 1 ECG pattern and symptoms. The prognosis of the asymptomatic patients as well as patients presented with a drug-induced type 1 ECG pattern seems to be good. Thus those with drug-induced type 1 ECG pattern without symptoms should be only considered for clinical follow-up. There is more uncertainty when symptoms or a spontaneous type 1 ECG pattern are present. Therapy should then be discussed on a case by case basis. Fig. 5 shows a flow-chart of our recommended approach.
Conclusion
A spontaneous type 1 ECG pattern and symptoms at diagnosis are predictive of a shorter time to first LTA event in the young. The risk of LTA is especially high in patients with both symptoms and a spontaneous type 1 ECG. These patients need to be considered for ICD implantation and/or chronic therapy with quinidine or hydroquinidine. Patients with a drug-induced type 1 ECG and without symptoms have a low arrhythmic risk and a good prognosis. In this population, regular clinical follow-up without specific treatment seems to be sufficient.
In asymptomatic patients with a spontaneous type 1 ECG pattern and in symptomatic patients without a spontaneous pattern, the risk appears to be relatively low and the decision to eventually implant an ICD or to introduce hydroquinidine therapy needs to be discussed case by case in highly experienced centers. The absence of a SCN5A mutation may then denote a lower risk of events and might be taken into account. Fever remains the most important trigger for LTA events and parents need to be advised to treat it aggressively with anti-pyretics. 
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